

Review article

Reported outcome measures in necrotising soft tissue infections: a systematic review

Jonathan Wackett¹, Bridget Devaney^{2,3,4}, Raymond Chau⁵, Joshua Ho⁵, Nicholas King⁵, Jasleen Grewal¹, Joshua Armstrong⁶, Biswadev Mitra^{2,4}

¹ Department of Medicine, Alfred Health, Melbourne, Australia

² Emergency and Trauma Centre, Alfred Health, Melbourne, Australia

³ Department of Intensive Care and Hyperbaric Medicine, Alfred Health, Melbourne, Australia

⁴ Department of Epidemiology and Preventative Medicine, Monash University, Melbourne, Australia

⁵ Monash Health, Melbourne, Australia

⁶ Barwon Health, Geelong, Australia

Corresponding author: Dr Bridget Devaney, Head of Hyperbaric Medicine, Alfred Health, 55 Commercial Road, Melbourne, VIC 3004, Australia

ORCID: [0000-0001-6521-418X](https://orcid.org/0000-0001-6521-418X)

b.devaney@alfred.org.au

Keywords

Fournier's gangrene; Gas gangrene; Hyperbaric oxygen treatment; Intensive care medicine; Systematic review

Abstract

(Wackett J, Devaney B, Chau R, Ho J, King N, Grewal J, Armstrong J, Mitra B. Reported outcome measures in necrotising soft tissue infections: a systematic review. *Diving and Hyperbaric Medicine*. 2024 31 March;54(1):47–56. [doi: 10.28920/dhm54.1.47-56](https://doi.org/10.28920/dhm54.1.47-56). PMID: 38507909.)

Introduction: There are inconsistencies in outcome reporting for patients with necrotising soft tissue infections (NSTI). The aim of this study was to evaluate reported outcome measures in NSTI literature that could inform a core outcome set (COS) such as could be used in a study of hyperbaric oxygen in this indication.

Methods: A systematic review of all NSTI literature identified from Cochrane, Ovid MEDLINE and Scopus databases as well as grey literature sources OpenGrey and the New York Academy of Medicine databases which met inclusion criteria and were published between 2010 and 2020 was performed. Studies were included if they reported on > 5 cases and presented clinical endpoints, patient related outcomes, or resource utilisation in NSTI patients. Studies did not have to include intervention. Two independent researchers then extracted reported outcome measures. Similar outcomes were grouped and classified into domains to produce a structured inventory. An attempt was made to identify trends in outcome measures over time and by study design.

Results: Three hundred and seventy-five studies were identified and included a total of 311 outcome measures. Forty eight percent (150/311) of outcome measures were reported by two or more studies. The four most frequently reported outcome measures were mortality without time specified, length of hospital stay, amputation performed, and number of debridements, reported in 298 (79.5%), 260 (69.3%), 156 (41.6%) and 151 (40.3%) studies respectively. Mortality outcomes were reported in 23 different ways. Randomised controlled trials (RCTs) were more likely to report 28-day mortality or 90-day mortality. The second most frequent amputation related outcome was level of amputation, reported in 7.5% (28/375) of studies. The most commonly reported patient-centred outcome was the SF-36 which was reported in 1.6% (6/375) of all studies and in 2/10 RCTs.

Conclusions: There was wide variance in outcome measures in NSTI studies, further highlighting the need for a COS.

Introduction

Necrotising soft tissue infections (NSTI) are a collection of rare but serious infections that can lead to widespread tissue destruction and threaten considerable morbidity and mortality. NSTI encompasses conditions such as necrotising fasciitis, Fournier's gangrene, necrotising cellulitis and necrotising myonecrosis.¹ A large Danish

registry-based study demonstrated all-cause mortality rates of 19% at 30 days, 25% at 90-days, and 30% at one-year.² Treatment modalities include early surgical debridement, broad spectrum antibiotics and often organ support in an intensive care unit, however there is ongoing discourse as to the effectiveness of adjuvant therapies such as hyperbaric oxygen treatment (HBOT) and intravenous immunoglobulin (IVIG) administration.¹

Treatment with hyperbaric oxygen involves breathing 100% oxygen at greater than atmospheric pressures, substantially increasing serum partial pressures of oxygen. There are a number of proposed physiological mechanisms by which repeated increased partial pressures of oxygen may improve outcomes in NSTI. Multiple retrospective observational studies and a recent meta-analysis demonstrate reduced in-hospital mortality in NSTI patients treated with HBOT, however Level 1 evidence is currently lacking and the use of HBOT varies between centres.³ Heterogeneity in outcome reporting limits the quality of data available for meta-analysis.

Thus, it follows that the selection of outcome measures for prospective trials is critical.⁴ A core outcome set (COS) is an agreed standardised set of outcomes that should be measured and reported, as a minimum, in all clinical trials in specific areas of health or health care.⁴ High quality prospective trials use outcomes that are predetermined, but in the absence of a COS, findings are variably reported, and reporting bias may be introduced.⁵ Currently, there is no consensus amongst clinicians, researchers and patients regarding the outcome measures that should be collected and reported in studies assessing potential interventions for NSTI.⁶ A Cochrane Review of interventions for NSTIs in adults demonstrated that only one third of included studies reported all the predetermined outcomes.⁷ Such inconsistencies preclude the synthesis of data in meta-analyses and reduce the quality of evidence available to form clinically relevant conclusions that ultimately benefit patient care.

The aim of this systematic review was to develop an inventory of outcome measures used in NSTI studies. We evaluated associations between methodological design and outcome reporting. It was expected that the findings will inform the development of a COS for NSTI, which will lead to enhanced ability to evaluate the efficacy of adjuvant therapies such as HBOT.

Methods

This systematic review was designed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline.⁸ The review protocol was developed *a priori* and registered with the International Prospective Register of Systematic Reviews (PROSPERO), registration number CRD42022330268. The inventory of reported outcome measures generated by this review will inform Delphi surveys and consensus meetings as part of a broader initiative to develop a COS in NSTI.

After the initial search, all steps were undertaken in duplicate by independent reviewers.

SEARCH STRATEGY

A comprehensive literature search was undertaken using Cochrane, Ovid MEDLINE and Scopus databases as well as grey literature sources OpenGrey and the New York Academy of Medicine databases. Searches were performed for a 10-year period (January 2010 – August 2020) to record an extensive list of outcomes being reported for this relatively rare group of conditions, as well as to identify how research in NSTI may have changed over time. Medical subject headings and keywords such as “*Necrotising soft tissue infections*”, “*Fournier gangrene*”, and “*Gas gangrene*” were combined using the “OR” operator to ensure a breadth of results were returned. An example of the full search strategy as was used for Ovid MEDLINE is provided in * [Appendix 1](#).

STUDY ELIGIBILITY

Studies were included if they related to NSTI and reported one or more patient outcomes provided they also met the following criteria:

Types of studies: All study designs were included except for case reports, case series of < 5 cases, case series that only express their outcomes individually or qualitatively (e.g., a case series of eight cases described in detail but with no pooling or tabulation of patient outcomes). These study designs were excluded to avoid outcome measures that are less relevant or achievable for larger studies.

Types of participants: We included studies that reported outcomes of NSTI patients of all ages, geographic locations, and disease phenotypes (necrotising fasciitis, Fournier’s gangrene etc) that were at any stage in the course of their disease (inpatient or outpatient).

Types of interventions: Studies of any/all interventions for NSTI were included. Studies not assessing an intervention were also included, provided they reported on patient outcomes.

Types of outcomes: Studies were included if they reported any patient related outcome or clinical endpoint, including outcomes related to mortality, morbidity, recovery, quality of life, and adverse events. Outcomes reported in the body of text, tables and/or figures were included. Patient and observer reported outcomes were included. Studies that did not include any patient centred outcomes or resource utilisation outcomes were excluded (e.g., laboratory-based studies reporting specific biomarkers only).

STUDY SELECTION PROCESS

All reviewers involved in the study selection process underwent training to ensure they understood the context of

Footnote: * Appendix 1 is available on DHM Journal’s website: <https://www.dhmjournal.com/index.php/journals?id=330>

the review, the inclusion/exclusion criteria and how to use the Covidence software prior to study screening.

The title and abstract of each study were screened independently and in duplicate by two reviewers (BD, JA, JW). The primary reason for exclusion at this stage was study design (e.g., case study or case series with < 5 cases). The full text of studies found to meet the inclusion criteria were then retrieved. Again, two reviewers (JA, JG, JH, JW, RC) reviewed each study independently and in duplicate. Disputes at either stage were reviewed and resolved by the senior reviewer (JW).

QUALITY ASSESSMENT

Examination and synthesis of data related to patients or treatment effects was not performed. To produce an exhaustive list of outcomes and to compare potential differences in reporting between different study designs, all relevant studies were included, regardless of methodology. Thus, no risk of bias or quality assessment of studies was performed, as we only sought to extract the relevant outcome measures that were reported in each study.

DATA EXTRACTION

Online software from Research Electronic Data Capture (REDCap) was used to extract and securely store data.⁹ Alongside the outcome measures reported by each study, we recorded each study's author, year of publication, country it was primarily conducted in, study design and number of NSTI patients included. We noted whether studies declared sources of funding or potential sources of bias, although this data is not presented here.

Data were extracted from each study independently and in duplicate by two reviewers (JG, JH, JW, NK, RC). Both primary and secondary outcomes were recorded.


DATA ANALYSIS

Following extraction in duplicate, the two sets of data were exported into Microsoft® Excel. Any discrepancies were flagged and reviewed by the senior reviewer (JW).

Outcomes that were similar but spelt or worded differently were reviewed by the senior reviewer to ensure the meaning was the same and subsequently merged, for example; “*days in hospital*” and “*length of hospital stay (days)*”. Many studies reported the same outcome measure but at different time points, such as; “*mortality at 7 days*”, “*mortality at 3 months*”, “*in-hospital mortality*”. In these cases, they were included as separate outcomes, as it is the intent of this study to identify the individual outcomes and time points that were considered important to researchers of NSTI. Ultimately, an individual list of outcomes that were reported by each study

Figure 1

Preferred reporting items for systematic reviews and meta-analyses (PRISMA) flow diagram; outcome reporting of patients with NSTI



was generated. This list was used to create a comprehensive outcome inventory.

One group has developed a taxonomy for outcome measures to increase the efficiency of searching resources and databases by facilitating uniformity of outcome classification.¹⁰ This taxonomy has been adopted by the Core Outcome Measures in Effectiveness Trials (COMET) initiative as well as the Cochrane Linked Data Project.¹⁰ With this work in mind, the outcome measures identified in this systematic review were organised into eleven different outcome domains and then classified under five core areas based on their subject matter; mortality, physiological/clinical, resource use, life impact and adverse outcomes.

Results

The online search retrieved 4,256 titles and they were exported to the reference management tool EndNote X8 where 1,069 duplicates were removed.¹¹ Remaining studies were input into the online systematic review software Covidence where a further 303 duplicates were identified and removed.¹² After abstracts had been screened, 436 studies were selected for full text review. Figure 1 outlines this process.

Table 1
Mortality/survival outcomes; ICU – intensive care unit; RCTs – randomised controlled trials

Outcome	% of total studies	n patients	Reported in % of prospective studies	Reported in % of RCTs	Reported in % of studies 2010–2015	Reported in % of studies 2016–2020
Mortality without time specified	79.5% (298/375)	267,990	45.1% (23/51)	20% (2/10)	85.5% (171/200)	72.6% (127/175)
In hospital mortality / 'survival to discharge'	25.1% (94/375)	11,3154	23.5% (12/51)	20% (2/10)	24.5% (49/200)	25.7% (45/175)
Survival time	6.7% (25/375)	48,607	11.7% (6/51)	0% (0/10)	8.5% (17/200)	4.6% (8/175)
30-day mortality	5.6% (21/375)	10,184	21.6% (11/51)	0% (0/10)	4.5% (9/200)	6.9% (12/175)
28-day mortality	5.3% (20/375)	5,465	21.6% (11/51)	40% (4/10)	4.5% (9/200)	6.3% (11/175)
90-day mortality	5.1% (19/375)	1,900	29.4% (15/51)	30% (3/10)	3.0% (6/200)	7.4% (13/175)
ICU mortality	3.5% (13/375)	1,273	3.9% (2/51)	0% (0/10)	3.0% (6/200)	4.0% (7/175)

Three hundred and seventy-five studies were included; references are provided in *[Appendix 2](#). Of these, 86% (324/375) of studies were retrospective which included a total of 276,119 patients and 2.7% (10/375) were randomised controlled trials including 904 patients. In total, 7,062 patients were included in prospective studies.

A total of 311 distinct outcomes were reported 2,629 times by the included studies. Of these, 48% (150/311) of outcome measures were reported by two or more studies. Outcome measures were classified into 11 outcome domains and are presented under the five core areas consistent with the taxonomy developed elsewhere; mortality, physiological/clinical, life impact, resource use and adverse events.¹⁰ These are detailed below. A full inventory of the outcomes reported, their relative frequency and their stratified domains can be found in *[Appendix 3](#).

Tables 1–5 show the most reported outcomes in each domain. Each table outlines the total number of studies that reported an outcome and the number of patients in those studies. The total pool of studies is also further subdivided into study design, either prospective or randomised controlled trials (RCT) and by year of publication, either 2010–2015 or 2016–2020, to give an indication on how outcome reporting may be changing over time.

CORE AREA: MORTALITY/SURVIVAL (TABLE 1)

Mortality without time specified was the most frequently reported mortality related outcome, appearing in 79.5% (298/375) of studies. Sixty percent (6/10) of RCTs reported a mortality outcome, of which four specified a time point. *28-day mortality* was the most commonly reported time point, appearing in 40% (4/10) of RCTs. *Ninety-day mortality* was more frequently reported in the second five-year period of extraction (2016–2020), being reported in 13/175 (7.4%) of included manuscripts. *Survival time* was less frequently reported among studies in the second five-year period at 9.7% (17/175), compared to 8.5% (17/200) in the earlier period of this study. A further 16 mortality related outcomes can be found in *[Appendix 3](#).

CORE AREA: PHYSIOLOGICAL/CLINICAL (TABLE 2)

Amputation performed was an outcome reported in 41.6% (156/375) of studies and 50% (5/10) of RCTs. The next most reported amputation related outcome, *level of amputation*, was reported in 7.5% (28/375) of studies but was not recorded in any RCTs. There were 13 other amputation related outcomes identified and can be found in *[Appendix 3](#), but none were reported by more than three studies.

Table 2
Physiological/clinical outcomes; NICCE – necrotizing infection clinical composite endpoint; RCTs – randomised controlled trials; SOFA – sequential organ failure assessment

Outcome	% of total studies	<i>n</i> patients	Reported in % of prospective studies	Reported in % of RCTs	Reported in % of studies 2010–15	Reported in % of studies 2016–20
Amputation outcomes						
Amputation performed	41.6% (156/375)	141,271	41.0% (25/51)	50% (5/10)	45% (90/200)	37.7% (66/175)
Level of amputation	7.5% (28/375)	8,133	7.8% (4/51)	0% (0/10)	9.5% (19/200)	5.1% (9/175)
Debridement outcomes						
Number of debridements required	40.3% (151/375)	110,122	33.3% (17/51)	40% (4/10)	37% (74/200)	45.1% (79/175)
Required debridement AND fasciotomy	1.3% (5/375)	362	0% (0/51)	0% (0/10)	1.5% (3/200)	1.1% (2/175)
Extent of debridement (cm ²)	1.1% (4/375)	1,258	0% (0/51)	0% (0/10)	0.5% (1/200)	1.7% (3/175)
Closure/reconstruction outcomes						
Skin graft requirement	23.5% (88/375)	8,129	15.7% (8/51)	10% (1/10)	25% (50/200)	21.7% (38/175)
Surgical flap requirement	11.7% (44/375)	2,628	2.0% (1/51)	0% (0/10)	11% (22/200)	12.6% (22/175)
Surgical reconstruction requirement	10% (38/375)	4,012	5.9% (3/51)	10% (1/10)	10% (20/200)	10.3% (18/175)
Primary wound closure	5.9% (22/375)	3,063	2.0% (1/51)	0% (0/10)	4% (8/200)	8.0% (14/175)
Split thickness skin graft requirement	4.3% (16/375)	808	2.0% (1/51)	10% (1/10)	5.5% (11/200)	2.9% (5/175)
Area healed by secondary intention	2.7% (10/375)	671	0% (0/51)	0% (0/10)	3.5% (7/200)	1.7% (3/175)

Table 2 continued.

Healing outcomes						
Wound healing time (cicatrisation time)	2.7% (10/375)	316	5.9% (3/51)	10% (1/10)	2.5% (5/200)	2.9% (5/175)
Time to cure	1.0% (3/375)	315	0% (0/51)	0% (0/10)	1% (2/200)	0.6% (1/175)
Other surgical outcomes						
Number of operations required	22.9% (86/375)	7,1081	9.8% (5/51)	0% (0/10)	22.5% (45/200)	23.4% (41/175)
Colostomy	20.0% (75/375)	17,348	11.8% (6/51)	10% (1/10)	18.5% (37/200)	21.7% (38/175)
Orchidectomy	12.3% (46/375)	13,838	3.9% (2/51)	10% (1/10)	10.5% (21/200)	14.3% (25/175)
Cystostomy	9.1% (34/375)	2,288	7.8% (4/51)	10% (1/10)	9.5% (19/200)	8.6% (15/175)
Suprapubic tube placement	5.6% (21/375)	12,190	2.0% (1/51)	0% (0/10)	3.5% (7/200)	8.0% (14/175)
Penectomy	4.0% (15/375)	12,501	2.0% (1/51)	0% (0/10)	3.5% (7/200)	4.6% (8/175)
Faecal diversion	3.2% (12/375)	9,832	2.0% (1/51)	0% (0/10)	3.0% (6/200)	3.4% (6/175)
Composite outcomes						
SOFA score (Day 14)	1.1% (4/375)	821	5.9% (3/51)	30% (3/10)	1.5% (3/200)	0.6% (1/175)
NICCE endpoint	0.8% (3/375)	778	3.9% (2/51)	20% (2/10)	0.5% (1/200)	1.1% (2/175)
SOFA score (Day 28)	0.5% (2/375)	821	2.0% (1/51)	10% (1/10)	0.5% (1/200)	0.6% (1/175)
m-SOFA (Day 14)	0.5% (2/375)	488	2.0% (1/51)	10% (1/10)	0.5% (1/200)	0.6% (1/175)

Number of debridements required was the most reported debridement related outcome, being reported in 40.3% (151/375) of total studies, including 33.3% (17/51) of prospective studies and 40% (4/10) of RCTs. No other debridement related outcomes were reported in more than five studies. A further 10 debridement related outcomes can be found in *[Appendix 3](#).

Skin graft requirement was reported in 23.5% (88/375) of studies including 15.7% (8/51) of prospective studies. Surgical flap requirement (without regard to the specific type, e.g. rotational, free etc) was reported in 11.7% (44/375) of papers but only 2.0% (1/51) of prospective studies. There were 26 other closure/reconstruction outcomes *[Appendix 3](#).

Healing related outcomes. A total of 18 healing related outcomes were identified and can be found in *[Appendix 3](#). Only two, however, were reported by more than two studies. The most frequently recorded outcome was wound healing time (cicatisation time) which could be found in 2.7% (10/375) of studies, including 316 patients.

Other Surgical outcomes. Number of procedures/surgeries required was recorded in 22.9% (86/375) of studies. Of those, 33.7% (29/86) also reported number of debridements required. There were 26 other surgical outcomes reported in *[Appendix 3](#).

Composite scores/endpoints. Numerous studies recorded sequential organ failure assessment (SOFA) scores at different stages of admission (e.g., score at Day 1, Day 2, Day 7 etc). In an attempt to distinguish between patient characteristics and outcomes, the authors decided to include SOFA scores at time points longer than 14 days as outcomes. This juncture was chosen as the day-14 modified 'mSOFA' has been validated for NSTI patients as a part of the Necrotising Infection Clinical Composite Endpoint (NICCE).¹³ A total of seven composite score outcomes are listed in *[Appendix 3](#), five of which were included in RCTs. The SOFA score (Day 14) was reported by 30% (3/10) of RCTs.

CORE AREA: LIFE IMPACT (TABLE 3)

Patient perspective related outcomes. Outcomes relating to the patient's perspective were recorded infrequently, with only four outcomes being reported by more than one study. The Medical Outcomes Short Form-36 questionnaire result (SF36) was the most reported patient perspective related outcome and was found in 1.6% (6/375) of all studies and was measured in 20% (2/10) of RCTs. Twenty more outcomes can be found in *[Appendix 3](#), all of which were only reported in one study each.

CORE AREA: RESOURCE USE (TABLE 4)

Length of hospital stay was reported in 69.3% (260/375) of studies, making it the second most commonly reported outcome overall after mortality without time specified. It was also reported in 47.1% (24/51) of prospective studies and 80% (8/10) of RCTs. Ventilation (days) was more frequently reported than ventilation (hours) appearing in 8.8% (33/375) of studies compared to 1.3% (5/375). There are 17 more resource use related outcomes listed in *[Appendix 3](#).

Discharge related outcomes. The most frequently reported discharge related outcome, discharge home, was reported in 4.8% (18/375) of studies, representing 40,466 patients. Discharge to skilled nursing facility was reported in 2.4% (9/375) of studies representing 113,368 patients. Nine further discharge related outcomes can be found in *[Appendix 3](#).

CORE AREA: ADVERSE EVENTS (TABLE 5)

A total of 102 adverse event/complication outcomes are listed and further classified into subcategories in *[Appendix 3](#). Eighty-four of these were recorded in five or less studies.

Discussion

The major strength of this review is its comprehensive nature. A systematic and predetermined approach was utilised, and by using broad search terms, the studies identified are likely a thorough representation of the NSTI literature. All stages of the review were conducted in duplicate to reduce recording bias. To the best of the authors' knowledge, this is the only study reporting systematically on outcome measures in contemporary NSTI literature. This review demonstrated variability in outcome reporting for NSTI. No single outcome was consistently found in every study and only four outcomes (mortality without time specified, length of hospital stay, amputation performed, number of debridements required) appeared in more than one third of studies. This heterogeneity of reporting limits evidence synthesis and the ability to compare data sets.¹⁴ Varied and inconsistent use of outcomes measures leaves meta-analyses unable to include data from all relevant studies or forces them to make assumptions about unclear reporting.^{7,15}

Studies representing less than five patients were excluded from this review, as were those that made no attempt to summarise or pool their results. Therefore, it is probable that certain novel or unique NSTI outcomes were missed in these smaller studies. This potential limitation was accepted given the broader intent of this study was to inform the development of a COS for future prospective trials. The frequently reported outcomes may also not be relevant to key stakeholders, as demonstrated by a profound lack of patient-centred outcome measures.

Table 3
Life impact outcomes; RCTs – randomised controlled trials

Outcome	% of total studies	<i>n</i> patients	Reported in % of prospective studies	Reported in % of RCTs	Reported in % of studies 2010–15	Reported in % of studies 2016–20
Short Form-36 (SF36)	1.6% (6/375)	324	3.9% (2/51)	20% (2/10)	1% (2/200)	2.3% (4/175)
Pain score (visual analogue scale)	0.5% (2/375)	92	2.0% (1/51)	20% (1/10)	0% (0/200)	1.1% (2/175)
Derriford appearance scale	0.5% (2/375)	92	0% (0/51)	0% (0/10)	0.5% (1/200)	0.6% (1/175)
Disability	0.5% (2/375)	597	0% (0/51)	0% (0/10)	0% (0/200)	1.1% (2/175)

Table 4
Resource use outcomes; ICU – intensive care unit; RCTs – randomised controlled trials

Outcome	% of total studies	<i>n</i> patients	Reported in % of prospective studies	Reported in % of RCTs	Reported in % of studies 2010–5	Reported in % of studies 2016–20
Resource outcomes						
Length of hospital stay	69.3% (260/375)	61,784	47.1% (24/51)	80% (8/10)	67.5% (135/200)	71.4% (125/175)
Length of ICU stay (days)	27.5% (103/375)	60,749	23.5% (12/51)	40% (4/10)	26% (52/200)	29.1% (51/175)
Ventilation (days)	8.8% (33/375)	4,127	13.7% (7/51)	30% (3/10)	9.5% (19/200)	8.0% (14/175)
Cost per patient	2.9% (11/375)	49,987	0% (0/51)	0% (0/10)	3.5% (7/200)	2.3% (4/175)
Ventilator-free days	2.4% (9/375)	11,730	7.8% (4/51)	3% (3/10)	2.5% (5/200)	2.3% (4/175)
Discharge outcomes						
Discharged home	4.8% (18/375)	40,466	5.9% (3/51)	10% (1/10)	4.5% (9/200)	5.1% (9/175)
Discharged to skilled nursing facility	2.4% (9/375)	113,368	2.0% (1/51)	0% (0/10)	1.5% (3/200)	3.4% (6/175)
Discharged to rehabilitation	1.6% (6/375)	1,576	2.0% (1/51)	0% (0/10)	2.5% (5/200)	1.7% (3/175)
Discharged to other hospital	1.6% (6/375)	10,237	0% (0/51)	0% (0/10)	1% (2/200)	2.3% (4/175)
Routine discharge	1.6% (6/375)	5,6151	2.0% (1/51)	0% (0/10)	2% (2/200)	1.1% (2/175)

Table 5
Adverse events outcomes; CVS – cardiovascular system; RCTs – randomised controlled trials

Outcome	% of total studies	<i>n</i> patients	Reported in % of prospective studies	Reported in % of RCTs	Reported in % of studies 2010–15	Reported in % of studies 2016–20
Septic shock	16.3% (61/375)	60,019	15.7% (8/51)	0% (0/10)	13% (26/200)	20% (35/175)
Sepsis	12.3% (46/375)	13,215	7.8% (4/51)	0% (0/10)	13.5% (27/200)	10.9% (19/175)
Organ failure/dysfunction	11.2% (42/375)	59,832	7.8% (4/51)	20% (2/10)	16% (32/200)	5.7% (10/175)
Acute kidney injury	8.8% (33/375)	10,037	7.8% (4/51)	0% (0/10)	8.5% (17/200)	9.1% (16/175)
Pneumonia	6.1% (23/375)	53,992	5.9% (3/51)	10% (1/10)	6.5% (13/200)	5.7% (10/175)
CVS complications (not otherwise spec)	5.6% (21/375)	116,920	3.9% (2/51)	0% (0/10)	5.5% (11/200)	5.7% (10/175)
Acute respiratory failure	5.6% (21/375)	63,160	2.0% (1/51)	10% (1/10)	6.5% (13/200)	4.6% (8/175)

One-hundred-and-two discreet adverse event outcomes were reported, many of them only appearing in a small number of studies. This is likely a representation of papers investigating NSTIs affecting specific anatomical regions (e.g., craniofacial NSTI) and reporting anatomically specific outcomes (e.g., proptosis) that would not be generalisable or relevant to all studies of NSTI.

When comparing outcome measures reported by studies published between 2010–2015 to those published between 2016–2020 a possible trend towards reporting more specific outcomes is noted. Vague outcome measures such as ‘organ failure/dysfunction’ and ‘mortality without time specified’ became less frequent, whilst more specific outcomes such as 28-day mortality, 30-day mortality, 90-day mortality appear more frequently. This is consistent with an increased emphasis on reporting transparency through preregistration of study protocols, which aims to decrease the risk of data being manipulated to support a hypothesis.¹⁶ Also of note is that patient reported outcomes such as Medical Outcomes Short Form-36 (SF-36) and pain score (visual analogue scale) were reported more frequently in the latter period, however the total number of studies utilising these outcomes remains very low.

Although a trend towards more specific outcome reporting is promising, in the absence of a COS the ability to generalise data is still limited. As has been previously noted in the literature, the limited number of studies that have investigated HBOT and other adjuvant therapies for NSTI have not reported consistent outcome sets,^{7,17–19} posing significant challenges in performing meta-analyses.³ This is a particularly important issue in NSTI given the rarity of the condition as well as the paucity of high-quality prospective

trials. Thus, there remains ongoing discourse regarding the role of HBOT and other measures in NSTI management. The inconsistency in reporting is evidenced in this review by mortality being reported in 23 different ways with varying time points or qualifiers.

Quality assessments of the included studies were not performed, as examination and synthesis of data was beyond the scope of this review. In developing a COS, it may be useful to further investigate the outcome measures utilised specifically in high quality studies. Potential weaknesses of this review include that the search was limited to English language results (although most studies identified and included were produced in countries where English is not the official language) and the exclusion of studies which reported solely laboratory-based outcome measures. Exclusion of qualitative outcomes that were neither pooled nor tabulated is another potential, although likely minor, limitation.

This study is the first in a series that aims to develop a COS for NSTI. It offers an inventory of outcomes reported in NSTI research which can now be proposed to an expert panel through a Delphi study, for determination of the most important outcomes to be included in future trials.

Conclusion

This systematic review provides a comprehensive inventory of the outcome measures currently being utilised for NSTI research and demonstrates a marked heterogeneity in outcome reporting. This inventory is a critical first step in the development of a COS, a process which is now underway in a separate Delphi study.

References

- 1 Stevens D, Bryant A. Necrotising soft-tissue infections. *N Engl J Med*. 2017;377:2253–65. doi: [10.1056/NEJMra1600673](https://doi.org/10.1056/NEJMra1600673). PMID: [29211672](https://pubmed.ncbi.nlm.nih.gov/29211672/).
- 2 Hedetoft M, Madsen M, Madsen L, Hyldegaard O. Incidence, comorbidity and mortality in patients with necrotising soft-tissue infections, 2005–2018: a Danish nationwide register-based cohort study. *BMJ Open*. 2020;10:e041302. doi: [10.1136/bmjopen-2020-041302](https://doi.org/10.1136/bmjopen-2020-041302). PMID: [33067303](https://pubmed.ncbi.nlm.nih.gov/33067303/). PMCID: [PMC7569942](https://pubmed.ncbi.nlm.nih.gov/PMC7569942/).
- 3 Hedetoft M, Bennett M, Hyldegaard O. Adjunctive hyperbaric oxygen treatment for necrotising soft-tissue infections: A systematic review and meta-analysis. *Diving Hyperb Med*. 2021;51:34–43. doi: [10.28920/dhm51.1.34-43](https://doi.org/10.28920/dhm51.1.34-43). PMID: [33761539](https://pubmed.ncbi.nlm.nih.gov/33761539/). PMCID: [PMC8081587](https://pubmed.ncbi.nlm.nih.gov/PMC8081587/).
- 4 Williamson P, Altman D, Bagley H, Barnes K, Blazeby J, Brookes S, et al. The COMET handbook: version 1.0. *Trials*. 2017;18:280. doi: [10.1186/s13063-017-1978-4](https://doi.org/10.1186/s13063-017-1978-4). PMID: [28681707](https://pubmed.ncbi.nlm.nih.gov/28681707/). PMCID: [PM5499094](https://pubmed.ncbi.nlm.nih.gov/PM5499094/).
- 5 Boers M, Kirwan J, Wells G, Beaton D, Gossec L, d'Agostino M, et al. Developing core outcome measurement sets for clinical trials: OMERACT filter 2.0. *J Clin Epidemiol*. 2014;67:745–53. doi: [10.1016/j.jclinepi.2013.11.013](https://doi.org/10.1016/j.jclinepi.2013.11.013). PMID: [24582946](https://pubmed.ncbi.nlm.nih.gov/24582946/).
- 6 COMET-Initiative. COMET Database. Liverpool, United Kingdom. [cited 2023 Apr 25]. Available from: <https://www.comet-initiative.org/Studies>.
- 7 Hua C, Bosc R, Sbidian E, De Prost N, Hughes C, Jabre P, et al. Interventions for necrotizing soft tissue infections in adults. *Cochrane Database Syst Rev*. 2018;5:CD011680. doi: [10.1002/14651858.CD011680.pub2](https://doi.org/10.1002/14651858.CD011680.pub2). PMID: [29851032](https://pubmed.ncbi.nlm.nih.gov/29851032/). PMCID: [PMC6494525](https://pubmed.ncbi.nlm.nih.gov/PMC6494525/).
- 8 Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ*. 2021;372:n71. doi: [10.1136/bmj.n71](https://doi.org/10.1136/bmj.n71). PMID: [33782057](https://pubmed.ncbi.nlm.nih.gov/33782057/). PMCID: [PMC8005924](https://pubmed.ncbi.nlm.nih.gov/PMC8005924/).
- 9 Harris P, Taylor R, Thielke R, Payne J, Gonzalez N, Conde J. Research electronic data capture (REDCap) – a metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform*. 2009;42:377–81. doi: [10.1016/j.jbi.2008.08.010](https://doi.org/10.1016/j.jbi.2008.08.010). PMID: [18929686](https://pubmed.ncbi.nlm.nih.gov/18929686/). PMCID: [PMC2700030](https://pubmed.ncbi.nlm.nih.gov/PMC2700030/).
- 10 Dodd S, Clarke M, Becker L, Mavergames C, Fish R, Williamson PR. A taxonomy has been developed for outcomes in medical research to help improve knowledge discovery. *J Clin Epidemiol*. 2018;96:84–92. doi: [10.1016/j.jclinepi.2017.12.020](https://doi.org/10.1016/j.jclinepi.2017.12.020). PMID: [29288712](https://pubmed.ncbi.nlm.nih.gov/29288712/). PMCID: [PMC5854263](https://pubmed.ncbi.nlm.nih.gov/PMC5854263/).
- 11 Clarivate Analytics. EndNote X8. Philadelphia, United States of America. [cited 2023 Apr 25]. Available from: <https://endnote.com/downloads>.
- 12 Vertias Health Innovation. Covidence systematic review software. Melbourne, Australia. [cited 2023 Apr 25]. Available from: <https://www.covidence.org/>.
- 13 Bulger E, May A, Dankner W, Maislin G, Robinson B, Shivran A. Validation of a clinical trial composite endpoint for patients with necrotizing soft tissue infections. *J Trauma Acute Care Surg*. 2017;83:622–7. doi: [10.1097/TA.0000000000001564](https://doi.org/10.1097/TA.0000000000001564). PMID: [28538644](https://pubmed.ncbi.nlm.nih.gov/28538644/).
- 14 Williamson P, Altman D, Blazeby J, Clarke M, Gargon E. Driving up the quality and relevance of research through the use of agreed core outcomes. *J Health Serv Res Policy*. 2012;17:1–2. doi: [10.1258/jhsrp.2011.011131](https://doi.org/10.1258/jhsrp.2011.011131). PMID: [22294719](https://pubmed.ncbi.nlm.nih.gov/22294719/).
- 15 Nawin F, Smeeing D, Houwert R, Leenen L, Hietbrink F. Time is of the essence when treating necrotizing soft tissue infections: a systematic review and meta-analysis. *World J Emerg Surg*. 2020;15:4. doi: [10.1186/s13017-019-0289-6](https://doi.org/10.1186/s13017-019-0289-6). PMID: [31921330](https://pubmed.ncbi.nlm.nih.gov/31921330/). PMCID: [PMC6950871](https://pubmed.ncbi.nlm.nih.gov/PMC6950871/).
- 16 Mitra-Majumdar M, Kesselheim A. reporting bias in clinical trials: progress toward transparency and next steps. *PLoS Med*. 2022;19:e1003894. doi: [10.1371/journal.pmed.1003894](https://doi.org/10.1371/journal.pmed.1003894). PMID: [35045078](https://pubmed.ncbi.nlm.nih.gov/35045078/). PMCID: [PMC8769309](https://pubmed.ncbi.nlm.nih.gov/PMC8769309/).
- 17 Devaney B, Frawley G, Frawley L, Pilcher DV. Necrotising soft tissue infections: the effect of hyperbaric oxygen on mortality. *Anaesth Intensive Care*. 2015;43:685–92. doi: [10.1177/0310057X1504300604](https://doi.org/10.1177/0310057X1504300604). PMID: [26603791](https://pubmed.ncbi.nlm.nih.gov/26603791/).
- 18 Soh CR, Pietrobon R, Freiburger JJ, Chew ST, Rajgor D, Gandhi M, et al. Hyperbaric oxygen therapy in necrotising soft tissue infections: a study of patients in the United States Nationwide Inpatient Sample. *Intensive Care Med*. 2012;38:1143–51. doi: [10.1007/s00134-012-2558-4](https://doi.org/10.1007/s00134-012-2558-4). PMID: [22527074](https://pubmed.ncbi.nlm.nih.gov/22527074/).
- 19 Creta M, Longo N, Arcaniolo D, Giannella R, Cai T, Cicalese A, et al. Hyperbaric oxygen therapy reduces mortality in patients with Fournier's Gangrene. Results from a multi-institutional observational study. *Minerva Urol Nefrol*. 2020;72:223–8. doi: [10.23736/S0393-2249.20.03696-6](https://doi.org/10.23736/S0393-2249.20.03696-6). PMID: [32083420](https://pubmed.ncbi.nlm.nih.gov/32083420/).

Acknowledgements

The authors acknowledge Monash University for providing access to Covidence systematic review software and Alfred Health for providing access to REDCap.

Conflicts of interest and funding: nil

Submitted: 10 November 2023

Accepted after revision: 1 January 2024

Copyright: This article is the copyright of the authors who grant *Diving and Hyperbaric Medicine* a non-exclusive licence to publish the article in electronic and other forms.